Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 2 institutions in 1 country.
Parakkal Jovvian GeorgeLaboratory Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States.
Radu MarchesThe Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Djamel Nehar-BelaidThe Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Jacques BanchereauThe Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
Sara LustigmanLaboratory Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States.
Jackson Laboratory · USNew York Blood Center · US
Funding
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combinationU01AI160421 · NIAID · NEW YORK BLOOD CENTER · PI LUSTIGMAN, SARA · 2021 to 2025
$3.7M
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combinationU01AI124260 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LUSTIGMAN, SARA · 2016 to 2020
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Th1/Tfh-like biased responses elicited by the rASP-1 innate adjuvant are dependent on TRIF and Type I IFN receptor pathways. · full record | OpenQuestion